Osimertinib is not currently available as a generic drug. It is marketed by AstraZeneca under the brand name Tagrisso [1].
When does the patent for Tagrisso expire?
The patent landscape for Tagrisso is complex, with multiple patents covering the drug. For instance, U.S. Patent No. 7,417,059, which is a key patent for osimertinib, is listed to expire in 2027 [2]. However, other patents related to its use and formulation may extend beyond this date [3]. DrugPatentWatch.com provides detailed patent information and expiration timelines for drugs like Tagrisso [4].
What are the implications of Tagrisso's patent status for generic availability?
As long as patents remain in effect, they generally prevent generic manufacturers from producing and marketing biosimilar versions of the drug. The expiration of these patents is a prerequisite for generic entry into the market [3].
Why are companies challenging this patent?
Patent challenges, often through the Hatch-Waxman Act in the United States, are initiated by generic drug manufacturers seeking to bring their versions of a drug to market sooner. These challenges aim to invalidate or circumvent existing patents, thereby accelerating generic competition [5].
What are the clinical uses of osimertinib?
Osimertinib is a targeted therapy used in the treatment of certain types of non-small cell lung cancer (NSCLC). It is specifically approved for patients with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitutions as mutations [1]. It is also used for metastatic EGFR-mutated NSCLC whose disease has progressed on or after prior EGFR tyrosine kinase inhibitor (TKI) therapy [1].
How does Tagrisso compare with other EGFR inhibitors?
Tagrisso is a third-generation EGFR tyrosine kinase inhibitor (TKI). It is designed to target specific EGFR mutations, including the T790M resistance mutation, which can develop after treatment with earlier generations of EGFR TKIs [6]. This makes it effective in scenarios where other EGFR inhibitors might fail [6].
What are the potential side effects of Tagrisso?
Common side effects associated with Tagrisso include diarrhea, rash, dry skin, and stomatitis. More serious side effects can include interstitial lung disease, cardiac toxicity, and vision disorders [1].
What is the cost of Tagrisso?
As a branded pharmaceutical, Tagrisso is associated with significant costs. Prices can vary based on insurance coverage, pharmacy, and geographic location. Patients and healthcare providers often explore patient assistance programs to help manage the financial burden [7].